Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Bria-OTS

Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at neoantigens · developed by BriaCell Therapeutics

Phase 1/2 Most advanced trial (none active)
BCTX Developer
1 Registered trials

What is Bria-OTS?

Bria-OTS is a tumor-infiltrating lymphocyte (TIL) cell therapy administered intradermally as part of a combination regimen with low-dose cyclophosphamide pretreatment, peginterferon alpha-2a, and tislelizumab for breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Tumor-infiltrating lymphocytes)
Targets
neoantigens (antigen)
Mechanism
Kills target cells, directed at neoantigens
Therapy area
Oncology
Developer
BriaCell Therapeutics Corporation (BCTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06471673 Phase 1/2 Breast Cancer Unknown BCTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerBreast TumorCancer of BreastCancer of the BreastMalignant Tumor of BreastTumors, Breast

More from BriaCell Therapeutics

SV-BR-1-GM Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BCTX page.

Follow BCTX, the company behind Bria-OTS

See BCTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BCTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.